The accompanying notes
are an integral part of these unaudited condensed financial statements.
The accompanying notes
are an integral part of these unaudited condensed financial statements.
The accompanying notes
are an integral part of these unaudited condensed financial statements.
The accompanying notes
are an integral part of these unaudited condensed financial statements.
NOTES TO CONDENSED
FINANCIAL STATEMENTS
(UNAUDITED)
Note
1 — Organization and Business Operations
McLaren
Technology Acquisition Corp. (the “Company”) is a blank check company incorporated as a Delaware corporation on February 24,
2021. The Company was incorporated for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization
or similar business combination with one or more businesses (the “Business Combination”). The Company has not selected any
specific Business Combination target and the Company has not, nor has anyone on its behalf, initiated any substantive discussions, directly
or indirectly, with any Business Combination target with respect to the Business Combination.
As of March
31, 2022, the Company had not commenced any operations. All activity for the period from February 24, 2021 (inception) through March 31,
2022 relates to the Company’s formation, the initial public offering (the “IPO”) described below and the search for
a target company for the Business Combination. The Company will not generate any operating revenues until after the completion of its
initial Business Combination, at the earliest. The Company will generate non-operating income in the form of interest income on its
cash and investments held in the trust account derived from the proceeds derived from the IPO. The Company has selected December 31 as
its fiscal year end.
The Company’s
sponsor is McLaren Technology Acquisition Sponsor LLC, a Delaware limited liability company (the “Sponsor”). The registration
statement for the Company’s IPO was declared effective on November 2, 2021 (the “Effective Date”). On November 5, 2021,
the Company consummated the IPO of 20,125,000 units (the “Units” and, with respect to the Class A common stock of
the Company, par value $0.0001 per share, included in the Units being offered, the “public shares”) at $10.00 per
Unit, including the full exercise of the underwriters’ over-allotment of 2,625,000 Units, generating gross proceeds to
the Company of $201,250,000, which is discussed in Note 3.
Commencing
December 23, 2021, holders of the 20,125,000 units sold in the Company’s initial public offering may elect to separately
trade the Company’s Class A common stock and warrants included in the units. Class A common stock and warrants that are
separated will trade on the Nasdaq Stock Market LLC under the symbols “MLAI” and “MLAIW,” respectively. No fractional
warrants will be issued upon separation of the units and only whole warrants will trade. Those units not separated will continue to trade
on the Nasdaq Stock Market LLC under the symbol “MLAIU.”
Simultaneously
with the consummation of the IPO, the Company consummated the private placement of 9,050,000 Warrants (the “Private Placement
Warrants”) at a price of $1.00 per Private Placement Warrant to the Sponsor, generating gross proceeds to the Company of $9,050,000,
which is described in Note 4.
Additionally,
simultaneously with the closing of the IPO, pursuant to a Subscription Agreement, dated November 2, 2021, by and between the Company and Mizuho
Securities USA LLC, the representative of the underwriters (the “representative”), the Company completed the private
sale of an aggregate of 300,000 shares of Class B common stock of the Company, par value $0.0001 per share (the “Representative
Shares”) at a purchase price of approximately $3.33 per Representative Share, generating gross proceeds to the Company of $1,000,000.
No underwriting discounts or commissions were paid with respect to such sale. The issuance of the Representative Shares was made pursuant
to the exemption from registration contained in Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”)
(see Note 5).
Transaction
costs amounted to $13,436,005 consisting of $4,025,000 of underwriting commissions, $7,043,750 of deferred underwriting
fees, $1,847,600, which represents the fair value of the Representative Shares in excess of cash paid, and $519,655 of other offering
costs, and was all charged to stockholders’ deficit.
The Company’s
management has broad discretion with respect to the specific application of the net proceeds of the IPO and sale of the Private Placement
Warrants, although substantially all of the net proceeds are intended to be applied generally toward consummating a Business Combination.
The Company’s Business Combination must be with one or more target businesses that together have a fair market value equal to at
least 80% of the net balance in the Trust Account (as defined below) (excluding the amount of deferred underwriting commissions held
in the Trust Account and taxes payable on the income earned on the Trust Account) at the time of the signing a definitive agreement in
connection with the Business Combination. However, the Company will only complete a Business Combination if the post-transaction company
owns or acquires 50% or more of the outstanding voting securities of the target or otherwise acquires a controlling interest in the
target business sufficient for it not to be required to register as an investment company under the Investment Company Act 1940, as amended
(the “Investment Company Act”). There is no assurance that the Company will be able to complete a Business Combination successfully.
Following
the closing of the IPO on November 5, 2021, $205,275,000 ($10.20 per Unit) from the net proceeds of the sale of Units in the
IPO and a portion of the proceeds of the sale of the Private Placement Warrants was deposited into a trust account (“Trust Account”)
located in the United States with Continental Stock Transfer & Trust Company acting as trustee, and will be invested only in U.S. government
securities, within the meaning set forth in Section 2(a)(16) of the Investment Company Act, having a maturity of 185 days or
less or in money market funds meeting certain conditions under Rule 2a-7 promulgated under the Investment Company Act which invest
only in direct U.S. government treasury obligations. Except with respect to interest earned on the funds held in the Trust Account that
may be released to the Company to pay its tax obligations and up to $100,000 of interest that may be used for its dissolution expenses,
if any, the funds held in the Trust Account will not be released from the Trust Account until the earliest to occur of: (1) the Company’s
completion of an initial Business Combination; (2) the redemption of any public shares properly submitted in connection with a stockholder
vote to amend the Company’s amended and restated certificate of incorporation (A) to modify the substance or timing of the
Company’s obligation to allow redemption in connection with the initial Business Combination or to redeem 100% of the public
shares if the Company does not complete the initial Business Combination within 15 months from the closing of the IPO (or up to 24 months
from the closing of the initial public offering if we extend the time to complete a Business Combination pursuant to the terms of the
Company’s amended and restated certificate of incorporation, the “Combination Period”) or (B) with respect to any
other provision relating to stockholders’ rights or pre-initial Business Combination activity; and (3) the redemption of the
public shares if the Company has not completed an initial Business Combination within the Combination Period, subject to applicable law.
The proceeds deposited in the Trust Account could become subject to the claims of the creditors, which would have priority than the claims
of the Company’s public stockholders.
The Company
will provide its public stockholders with the opportunity to redeem all or a portion of their public shares upon the completion of the
initial Business Combination either (1) in connection with a stockholder meeting called to approve the initial Business Combination
or (2) by means of a tender offer. The decision as to whether the Company will seek stockholder approval of a proposed Business Combination
or conduct a tender offer will be made by the Company, solely in its discretion, and will be based on a variety of factors such as the
timing of the transaction and whether the terms of the transaction would require us to seek stockholder approval under applicable law
or stock exchange listing requirement. The stockholders will be entitled to redeem all or a portion of the public shares upon the completion
of the initial Business Combination at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the Trust
Account as of two business days prior to the consummation of the initial Business Combination, including interest earned on the funds
held in the Trust Account and not previously released to the company to pay its taxes, divided by the number of the outstanding public
shares, subject to the limitations described herein. The amount in the Trust Account is initially $10.20 per public share. The per
share amount the Company will distribute to investors who properly redeem their shares will not be reduced by the deferred underwriting
commissions the Company will pay to the underwriters.
The Company
will have only the Combination Period to complete the initial Business Combination. However, if the Company has not completed the initial
Business Combination within the Combination Period, the Company will (1) cease all operations except for the purpose of winding up;
(2) as promptly as reasonably possible but not more than ten business days thereafter, redeem the public shares, at a per-share price,
payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest (less up to $100,000 of interest
to pay dissolution expenses), divided by the number of the outstanding public shares, which redemption will completely extinguish public
stockholders’ rights as stockholders (including the right to receive further liquidating distributions, if any); and (3) as
promptly as reasonably possible following such redemption, subject to the approval of the Company’s remaining stockholders and the
Company’s board of directors, liquidate and dissolve, subject in each case to the Company’s obligations under Delaware law
to provide for claims of creditors and the requirements of other applicable law.
The Sponsor,
directors and officers have entered into a letter agreement with the Company, pursuant to which they have agreed to waive: (1) their
redemption rights with respect to any Founder Shares (defined below) and public shares held by them in connection with the completion
of the initial Business Combination; (2) their redemption rights with respect to any Founder Shares and public shares held by them
in connection with a stockholder vote to approve an amendment to the Company’s amended and restated certificate of incorporation
(A) to modify the substance or timing of the Company’s obligation to allow redemption in connection with the initial Business
Combination or to redeem 100% of the public shares if the Company does not complete its initial Business Combination within the Combination
Period or (B) with respect to any other provision relating to stockholders’ rights or pre- initial Business Combination activity;
and (3) their rights to liquidating distributions from the trust account with respect to any Founder Shares they hold if the Company
fail to complete its initial Business Combination within the Combination Period (4) vote any shares of Class B common stock held
by them and any public shares purchased during or after the IPO in favor of the initial Business Combination.
The Sponsor
has agreed that it will be liable to the Company if and to the extent any claims by a third party (other than the Company’s independent
auditors) for services rendered or products sold to the Company, or a prospective target business with which the Company has entered into
a written letter of intent, confidentiality or similar agreement or Business Combination agreement, reduce the amount of funds in the
trust account to below the lesser of (1) $10.20 per public share or (2) the actual amount per share held in the Trust Account
as of the date of the liquidation of the Trust Account if less than $10.20 per share due to reductions in the value of the trust
assets, less taxes payable, provided that such liability will not apply to any claims by a third party or prospective target business
who executed a waiver of any and all rights to the monies held in the Trust Account (whether or not such waiver is enforceable) nor will
it apply to any claims under the Company’s indemnity of the underwriters of the IPO against certain liabilities, including liabilities
under the Securities Act. However, the Company has not asked the Sponsor to reserve for such indemnification obligations, nor has the
Company independently verified whether the Sponsor has sufficient funds to satisfy its indemnity obligations and the Company believes
that the Sponsor’s only assets are securities of the Company. Therefore, the Company cannot assure that the Sponsor would be able
to satisfy those obligations. None of the Company’s officers or directors will indemnify the Company for claims by third parties
including, without limitation, claims by vendors and prospective target businesses.
Liquidity
and Capital Resources
The Company’s
liquidity needs up to its IPO had been satisfied through a payment from the Sponsor of $25,000 (see Note 5) for the Founder Shares
to cover certain offering costs and the loan under an unsecured promissory note from the Sponsor of up to $300,000 (see Note 5).
The Company’s liquidity needs since its IPO and through March 31, 2022 have been satisfied through proceeds from the Private Placement.
At March 31, 2022, the Company had $751,400 in its operating bank account and working capital of $874,683. The Company’s balance
in the operating bank account mainly consisted of the portion of proceeds of the sale of the Private Placement Warrants not held in the
Trust Account.
In addition,
in order to finance transaction costs in connection with a Business Combination, the Company’s Sponsor or an affiliate of the Sponsor
or certain of the Company’s officers and directors may, but are not obligated to, provide the Company Working Capital Loans, as
defined below (see Note 5). As of March 31, 2022 and December 31, 2021, there were no amounts outstanding under any Working Capital Loans.
Based on
the foregoing, management believes that the Company will have sufficient working capital and borrowing capacity to meet its needs through
the earlier of the consummation of a Business Combination or one year from this filing. Over this time period, the Company will be using
these funds for paying existing accounts payable, identifying and evaluating prospective initial Business Combination candidates, performing
due diligence on prospective target businesses, paying for travel expenditures, selecting the target business to merge with or acquire,
and structuring, negotiating and consummating the Business Combination.
Going Concern
In connection
with the Company’s assessment of going concern considerations in accordance with the authoritative guidance in Financial Accounting
Standard Board (“FASB”) Accounting Standards Update (“ASU”) 2014-15, “Disclosures of Uncertainties about
an Entity’s Ability to Continue as a Going Concern,” management has determined that the mandatory liquidation and subsequent
dissolution described earlier in Note 1, should the Company be unable to complete a business combination, raises substantial doubt about
the Company’s ability to continue as a going concern. The Company has until February 5, 2023, 15 months from the closing of the
IPO, to consummate a Business Combination. It is uncertain that the Company will be able to consummate a Business Combination by the specified
period. If a Business Combination is not consummated by February 5, 2023, there will be a mandatory liquidation and subsequent dissolution.
These unaudited condensed financial statements do not include any adjustments relating to the recovery of the recorded assets or the classification
of the liabilities that might be necessary should the Company be unable to continue as a going concern. The Company intends to complete
a business combination before the mandatory liquidation date. However, there can be no assurance that the Company will be able to consummate
any business combination by February 5, 2023.
Risks and Uncertainties
Management
is currently evaluating the impact of the COVID-19 pandemic and Russia-Ukraine war and has concluded that while it is reasonably possible
that the virus and war could have a negative effect on the Company’s financial position, results of its operations and/or search
for a target company, the specific impact is not readily determinable as of the date of these unaudited condensed financial statements.
The unaudited condensed financial statements do not include any adjustments that might result from the outcome of this uncertainty.
Note
2 — Significant Accounting Policies
Basis
of Presentation
The accompanying
unaudited condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United
States of America (“US GAAP”) for interim financial information and in accordance with the instructions to Form 10-Q and Article
10 of Regulation S-X of the U.S. Securities and Exchange Commission (the “SEC”). Certain information or footnote disclosures
normally included in unaudited condensed financial statements prepared in accordance with US GAAP have been condensed or omitted, pursuant
to the rules and regulations of the SEC for interim financial reporting. Accordingly, they do not include all the information and footnotes
necessary for a complete presentation of financial position, results of operations, or cash flows. In the opinion of management, the accompanying
unaudited condensed financial statements include all adjustments, consisting of a normal recurring nature, which are necessary for a fair
presentation of the financial position, operating results and cash flows for the periods presented.
The accompanying
unaudited condensed financial statements should be read in conjunction with the Company’s Form 10-K for the period ended December
31, 2021 as filed with the SEC on April 15, 2022, which contains the audited financial statements and notes thereto. The interim results
for the three months ended March 31, 2022 are not necessarily indicative of the results to be expected for the year ending December 31,
2022 or for any future interim periods.
Emerging
Growth Company Status
The Company
is an “emerging growth company,” as defined in Section 2(a) of the Securities Act, as modified by the Jumpstart Our Business
Startups Act of 2012 (the “JOBS Act”), and it may take advantage of certain exemptions from various reporting requirements
that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required
to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding
executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory
vote on executive compensation and approval of any golden parachute payments not previously approved.
Further,
Section102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting
standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not
have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards.
The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply
to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such
extended transition period which means that when a standard is issued or revised and it has different application dates for public or
private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt
the new or revised standard. This may make comparison of the Company’s unaudited condensed financial statements with another public
company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition
period difficult or impossible because of the potential differences in accounting standards used.
Use of
Estimates
The preparation
of the unaudited condensed financial statements in conformity with US GAAP requires management to make estimates and assumptions that
affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial
statements. Making estimates requires management to exercise significant judgement. It is at least reasonably possible that the estimate
of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management
considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual
results could differ significantly from those estimates.
Cash
and Cash Equivalents
The
Company considers all short-term investments with an original maturity of three months or less when purchased to be cash
equivalents. The Company held no cash equivalents as of March 31, 2022. The Company held U.S. Treasury Bills with a maturity of less than three months
in the amount of $205,274,080 which it considers as cash equivalents as of December 31, 2021.
Cash
and Securities Held in Trust Account
As of March
31, 2022, investment in the Company’s Trust Account consisted of $28,489 cash and $205,316,512 in U.S. Treasury Securities.
As of December 31, 2021, investment in the Company’s Trust Account consisted of $13,115 cash and $205,274,080 in U.S.
Treasury Securities. All of the U.S. Treasury Securities held at March 31, 2022 which were purchased on March 10, 2022 will mature on June
21, 2022. The Company earned interest of $57,806 for the three months ended March 31, 2022. The Company did not withdraw any of the interest
income from the Trust Account to pay its tax obligations.
The Company
classifies its United States Treasury securities as held-to-maturity in accordance with FASB ASC Topic 320 “Investments - Debt and
Equity Securities.” Held-to-maturity securities are those securities which the Company has the ability and intent to hold until
maturity. Held-to-maturity treasury securities are recorded at amortized cost and adjusted for the amortization or accretion of premiums
or discounts.
A decline
in the market value of held-to-maturity securities below cost that is deemed to be other than temporary, results in an impairment that
reduces the carrying cost to such securities’ fair value. The impairment is charged to earnings and a new cost basis for the security
is established. To determine whether an impairment is other than temporary, the Company considers whether it has the ability and intent
to hold the investment until a market price recovery and considers whether evidence indicating the cost of the investment is recoverable
outweighs evidence to the contrary. Evidence considered in this assessment includes the reasons for the impairment, the severity and the
duration of the impairment, changes in value subsequent to year-end, forecasted performance of the investee, and the general market condition
in the geographic area or industry in which the investee operates.
Premiums
and discounts are amortized or accreted over the life of the related held-to-maturity security as an adjustment to yield using the effective-interest
method. Such amortization and accretion are included in the “interest income” line item in the statements of operations. Interest
income is recognized when earned. The carrying value, excluding gross unrealized holding gains, and fair value of held to maturity securities
at March 31, 2022 and December 31, 2021 are as follows:
| |
Carrying Value as of March 31, 2022 | | |
Gross Unrealized Gains | | |
Gross Unrealized Losses | | |
Fair Value as of March 31,
2022 | |
U.S. Treasury Securities | |
$ | 205,316,512 | | |
$ | — | | |
$ | (34,342 | ) | |
$ | 205,282,170 | |
Cash | |
| 28,489 | | |
| — | | |
| — | | |
| 28,489 | |
| |
$ | 205,345,001 | | |
$ | — | | |
$ | (34,342 | ) | |
$ | 205,310,659 | |
| |
Carrying Value as of December 31, 2021 | | |
Gross Unrealized Gains | | |
Gross Unrealized Losses | | |
Fair Value as of December 31,
2021 | |
U.S. Treasury Securities | |
$ | 205,274,080 | | |
$ | 920 | | |
$ | — | | |
$ | 205,275,000 | |
Cash | |
| 13,115 | | |
| — | | |
| — | | |
| 13,115 | |
| |
$ | 205,287,195 | | |
$ | 920 | | |
$ | — | | |
$ | 205,288,115 | |
Common
Stock Subject to Possible Redemption
All of the 20,125,000 public shares
contain a redemption feature which allows for the redemption of such public shares in connection with the Company’s liquidation,
if there is a stockholder vote or tender offer in connection with the Business Combination and in connection with certain amendments to
the Company’s amended and restated certificate of incorporation. In accordance with the SEC and its guidance on redeemable equity
instruments, which has been codified in ASC 480-10-S99, redemption provisions not solely within the control of a company require common
stock subject to redemption to be classified outside of permanent equity. Ordinary liquidation events, which involve the redemption and
liquidation of all of the entity’s equity instruments, are excluded from the provisions of ASC 480. Accordingly, at March 31,
2022 and December 31, 2021, all shares of common stock subject to possible redemption are presented as temporary equity, outside of the
stockholders’ deficit section of the Company’s financial statements.
The Company
recognizes changes in redemption value immediately as they occur and adjusts the carrying value of redeemable common stock to equal the
redemption value at the end of each reporting period. Increases or decreases in the carrying amount of redeemable common stock are affected
by charges against additional paid in capital and accumulated deficit.
The Class
A common stock subject to possible redemption reflected on the balance sheets as of March 31, 2022 and December 31, 2021 is reconciled
in the following table:
Gross Proceeds from IPO | |
$ | 210,250,000 | |
Proceeds allocated to Public Warrants | |
| (4,628,750 | ) |
Class A common stock issuance costs | |
| (13,147,623 | ) |
Accretion of carrying value to redemption value | |
| 21,801,373 | |
Class A common stock subject to possible redemption | |
$ | 205,275,000 | |
Offering
Costs associated with the Initial Public Offering
The Company
complies with the requirements of the ASC 340-10-S99-1. Offering costs consisted of legal, accounting, underwriting fees and other costs
incurred through the IPO that were directly related to the IPO. Offering costs amounted to $13,436,005 and were charged to temporary
equity upon the completion of the IPO.
Fair
Value of Financial Instruments
The Company
applies ASC Topic 820, Fair Value Measurement (“ASC 820”), which establishes a framework for measuring fair value
and clarifies the definition of fair value within that framework. ASC 820 defines fair value as an exit price, which is the price that
would be received for an asset or paid to transfer a liability in the Company’s principal or most advantageous market in an orderly
transaction between market participants on the measurement date. The fair value hierarchy established in ASC 820 generally requires an
entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Observable inputs
reflect the assumptions that market participants would use in pricing the asset or liability and are developed based on market data obtained
from sources independent of the reporting entity. Unobservable inputs reflect the entity’s own assumptions based on market data
and the entity’s judgments about the assumptions that market participants would use in pricing the asset or liability and are to
be developed based on the best information available in the circumstances.
The carrying
amounts reflected in the balance sheets for current assets and current liabilities approximate fair value due to their short-term nature.
Level 1
— Assets and liabilities with unadjusted, quoted prices listed on active market exchanges. Inputs to the fair value measurement
are observable inputs, such as quoted prices in active markets for identical assets or liabilities.
Level 2
— Inputs to the fair value measurement are determined using prices for recently traded assets and liabilities with similar underlying
terms, as well as direct or indirect observable inputs, such as interest rates and yield curves that are observable at commonly quoted
intervals.
Level 3
— Inputs to the fair value measurement are unobservable inputs, such as estimates, assumptions, and valuation techniques when little
or no market data exists for the assets or liabilities.
Derivative
Financial Instruments
The Company
evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives
in accordance with ASC Topic 815, “Derivatives and Hedging”. Derivative instruments are initially recorded at fair value on
the grant date and re-valued at each reporting date, with changes in the fair value reported in the statements of operations. Derivative
assets and liabilities are classified in the balance sheets as current or non-current based on whether or not net-cash settlement or conversion
of the instrument could be required within 12 months of the balance sheet date.
Income
Taxes
The Company
accounts for income taxes under FASB ASC 740, “Income Taxes” (“ASC 740”). ASC 740 requires the recognition of
deferred tax assets and liabilities for both the expected impact of differences between the unaudited condensed financial statements and
tax basis of assets and liabilities and for the expected future tax benefit to be derived from tax loss and tax credit carry forwards.
ASC 740 additionally requires a valuation allowance to be established when it is more likely than not that all or a portion of deferred
tax assets will not be realized.
ASC 740
also clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements and prescribes
a recognition threshold and measurement process for financial statement recognition and measurement of a tax position taken or expected
to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon
examination by taxing authorities. ASC 740 also provides guidance on derecognition, classification, interest and penalties, accounting
in interim period, disclosure and transition. The Company recognizes accrued interest and penalties related to unrecognized tax benefits,
if any, as income tax expense. There were no unrecognized tax benefits or uncertain tax positions as of March 31, 2022 and December 31,
2021, and, as such, no amounts accrued for interest and penalties as of March 31, 2022 and December 31, 2021. The Company is currently
not aware of any issues under review that could result in significant payments, accruals, or material deviation from its position.
Warrants
The Company
accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant’s specific
terms and applicable authoritative guidance in FASB ASC 480, “Distinguishing Liabilities from Equity” (“ASC 480”)
and ASC 815, “Derivatives and Hedging” (“ASC 815”). The assessment considers whether the warrants are freestanding
financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of
the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company’s own common
stock and whether the warrant holders could potentially require “net cash settlement” in a circumstance outside of the Company’s
control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted
at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding.
For issued
or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component
of additional paid-in capital at the time of issuance. For issued or modified warrants that do not meet all of the criteria for equity
classification, the warrants are required to be recorded at their initial fair value on the date of issuance, and each balance sheet date
thereafter. The Company accounts for its outstanding warrants as equity-classified instruments.
Concentration
of Credit Risk
Financial
instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution
which, at times, may exceed the Federal Depository Insurance Coverage of $250,000. At March 31, 2022 and December 31, 2021, the Company
had not experienced losses on this account and management believes the Company was not exposed to significant risks on such account.
Net Loss
Per Common Share
The Company
complies with the accounting and disclosure requirements of FASB ASC Topic 260, “Earnings Per Share.” Net loss per share of
common stock is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period,
excluding common stock subject to forfeiture. At March 31, 2022 and December 31, 2021, the Company did not have any dilutive securities
and other contracts that could, potentially, be exercised or converted into common stock and then share in the earnings of the Company.
As a result, diluted net loss per share of common stock is the same as basic net loss per share of common stock for the period presented.
|
|
For the three months ended March 31, 2022 |
|
|
For the period from
February 24, 2021 (Inception) through
March 31, 2021 |
|
|
|
Class A |
|
|
Class B |
|
|
Class A |
|
|
Class B |
|
Basic and diluted net loss per share: |
|
|
|
|
|
|
|
|
|
|
|
|
Numerator: |
|
|
|
|
|
|
|
|
|
|
|
|
Allocation of net loss |
|
$ |
(182,027 |
) |
|
$ |
(45,507 |
) |
|
$ |
- |
|
|
$ |
(694 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Denominator: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted-average shares outstanding including common stock subject to redemption |
|
|
20,125,000 |
|
|
|
5,031,250 |
|
|
|
- |
|
|
|
5,031,250 |
|
Basic and diluted net loss per share |
|
$ |
(0.01 |
) |
|
$ |
(0.01 |
) |
|
$ |
- |
|
|
$ |
(0.00 |
) |
Recent
Accounting Pronouncements
The Company’s
management does not believe that any recently issued, but not effective, accounting standards, if currently adopted, would have a material
effect on the accompanying financial statements.
Note
3 — Initial Public Offering
On November
5, 2021, the Company sold 20,125,000 Units, including the full exercise of the underwriters’ over-allotment option to
purchase 2,625,000 Units, at a purchase price of $10.00 per Unit. Each Unit consisted of one share of Class A common
stock, an aggregate of 20,125,000 shares, and one-half of one redeemable public warrant, an aggregate of 10,062,500 public warrants. Each
whole public warrant will entitle the holder to purchase one share of Class A common stock at an exercise price of $11.50 per whole share,
subject to adjustment (see Note 7).
Note
4 — Private Placement
Simultaneously
with the closing of the IPO, the Company’s Sponsor purchased an aggregate of 9,050,000 Private Placement Warrants at a
price of $1.00 per warrant in a private placement, for an aggregate purchase price of $9,050,000. Each whole private placement warrant
will entitle the holder to purchase one share of Class A common stock at an exercise price of $11.50 per whole share, subject to
adjustment.
The Private
Placement Warrants may not be transferred, assigned or sold until 30 days after the consummation of an initial Business Combination, and
will not be redeemable by the Company. The initial purchasers, or their permitted transferees, have the option to exercise the Private
Placement Warrants on a cashless basis. Otherwise, the Private Placement Warrants have terms and provisions that are identical to those
of the warrants sold as part of the Units in the IPO.
Note
5 — Related Party Transactions
Founder
Shares
On March
9, 2021, the Sponsor purchased 8,625,000 shares of Class B common stock, par value $0.0001 (the “Founder Shares”),
for an aggregate purchase price of $25,000, or approximately $0.003 per share. On June 23, 2021, the Sponsor returned to the Company,
at no cost, an aggregate of 2,875,000 Founder Shares, which the Company cancelled. On October 1, 2021, the Sponsor returned
to the Company, at no cost, an aggregate of 718,750 Founder Shares, which the Company cancelled, resulting in an aggregate of 5,031,250 Founder
Shares outstanding and held by the Sponsor, or approximately $0.005 per share. Up to 656,250 Founder Shares were
subject to forfeiture by the Sponsor depending on the extent to which the underwriters’ over-allotment option is exercised. As
a result of the full exercise of the over-allotment option by the underwriters upon the consummation of the IPO, these shares are no longer
subject to forfeiture.
On November
5, 2021, the Sponsor forfeited and returned, and the Company then cancelled, 300,000 Founder Shares at no cost, and the representative
purchased 300,000 shares of Class B common stock, for an aggregate purchase price of $1,000,000, in connection with the closing
of the IPO. Additionally, on November 5, the Sponsor transferred 50,000 Founder Shares to the representative as additional compensation
for underwriting the IPO (see Note 6).
The initial
stockholders have agreed not to transfer, assign or sell any of their Founder Shares until the earlier to occur of: (A) one year after
the completion of the initial Business Combination and (B) the date on which the Company completes a liquidation, merger, capital stock
exchange or other similar transaction after the initial Business Combination that results in all of its stockholders having the right
to exchange their Class A common stock for cash, securities or other property (the “lock-up”). Notwithstanding the foregoing,
if the closing price of the Company’s Class A common stock equals or exceeds $12.00 per share (as adjusted for stock splits, stock
dividends, reorganizations, recapitalizations and the like) for any 20 trading days within any 30-trading day period commencing at least
150 days after the initial Business Combination, the Founder Shares will be released from the lock-up.
Promissory
Note — Related Party
On March
1, 2021, the Sponsor agreed to loan the Company up to $300,000 to be used for a portion of the expenses of the IPO. This loan was
non-interest bearing, unsecured and due at the earlier of December 31, 2021 or the closing of the IPO. As of March 31, 2022 and December
31, 2021, the Company had no outstanding borrowings on the promissory note.
Working
Capital Loans
In addition,
in order to fund working capital deficiencies or finance transaction costs in connection with an intended Business Combination, the Sponsor
or an affiliate of the Sponsor, or certain of the Company’s officers and directors may, but are not obligated to, loan the Company
funds as may be required on a non-interest bearing basis (“Working Capital Loans”). If the Company completes the initial Business
Combination, the Company would repay the Working Capital Loans. In the event that the initial Business Combination does not close, the
Company may use a portion of the working capital held outside the Trust Account to repay the Working Capital Loans but no proceeds from
the Trust Account would be used to repay the Working Capital Loans. Up to $1,500,000 of such Working Capital Loans may be convertible
into warrants of the post-Business Combination entity at a price of $1.00 per warrant at the option of the lender. Such warrants
would be identical to the Private Placement Warrants. Except as set forth above, the terms of the Working Capital Loans, if any, have
not been determined and no written agreements exist with respect to such loans. As of March 31, 2022 and December 31, 2021, the Company
had no borrowings under the Working Capital Loans.
Administrative
Support Fee
Commencing
on the date that our securities were first listed on the Nasdaq Global Market, the Company agreed to pay an affiliate of the Sponsor, $10,000 per
month for office space, utilities and secretarial and administrative support services. Upon completion of the initial Business Combination
or our liquidation, we will cease paying these monthly fees. The Company incurred $30,000 in administrative support service expense for
the three months ended March 31, 2022. At March 31, 2022 and December 31, 2021, a total of $10,000 was accrued for amounts owed by
the Company to the Sponsor under the administrative support agreement.
Note 6 — Commitments
and Contingencies
Registration
Rights
The holders
of the (i) Founder Shares, which were issued in a private placement prior to the closing of the IPO, (ii) Private Placement Warrants,
which were issued in a private placement simultaneously with the closing of the IPO (and the shares of Class A common stock underlying
such Private Placement Warrants) and (iii) warrants that may be issued upon conversion of Working Capital Loans have registration rights
that require the Company to register a sale of any of the Company’s securities held by them pursuant to a registration rights agreement
which was signed on November 5, 2021. The holders of these securities are entitled to make up to three demands, excluding short form demands,
that the Company registers such securities. In addition, the holders have certain “piggy-back” registration rights with respect
to registration statements filed subsequent to the Company’s completion of its initial Business Combination. The Company will bear
the expenses incurred in connection with the filing of any such registration statements.
Underwriting
Agreement
On November
5, 2021, the Company paid a cash underwriting discount of 2.0% per Unit, or $4,025,000.
Additionally,
the underwriters are entitled to a deferred underwriting discount of 3.5% of the gross proceeds of the IPO, or $7,043,750, upon the
completion of the Company’s initial Business Combination.
Representative’s
Common Stock
On November
5, 2021, the Sponsor forfeited and returned, and the Company then cancelled 300,000 Founder Shares at no cost, and the representative
purchased 300,000 Class B shares, for an aggregate purchase price of $1,000,000. The Company estimated the fair value of these 300,000 Class
B shares to be $2,440,800 and has recorded the $1,440,800 excess of fair value of the shares above the cash paid as an offering
cost, which was recorded as a charge to stockholders’ deficit. Additionally, on November 5, 2021, the Sponsor transferred 50,000 Founder
Shares to the representative for no cost. The Company estimated the fair value of these shares to be $406,800 which was recorded
as an offering cost and charged to stockholders’ deficit.
The representative
will be subject to the same restrictions and other agreements of the Sponsor with respect to the Founder Shares. The Founder Shares transferred
to the representative will be subject to the same concessions as those applied to the Founder Shares held by the Sponsor in accordance
with the terms of a Business Combination.
Note
7 — Stockholders’ Deficit
Preferred
Stock — The Company is authorized to issue 1,000,000 shares of preferred stock with a par value of $0.0001 and
with such designations, voting and other rights and preferences as may be determined from time to time by the Company’s board of
directors. At March 31, 2022 and December 31, 2021, there were no shares of preferred stock issued or outstanding.
Class
A Common stock — The Company is authorized to issue 100,000,000 shares of Class A common stock with a par
value of $0.0001 per share. At March 31, 2022 and December 31, 2021, there were no shares
of Class A common stock issued and outstanding (excluding 20,125,000 shares subject to possible redemption).
Class
B Common stock — The Company is authorized to issue 10,000,000 shares of Class B common stock with a par
value of $0.0001 per share. At March 31, 2022 and December 31, 2021, there were 5,031,250 shares of Class B common stock
issued and outstanding.
Stockholders
of record are entitled to one vote for each share held on all matters to be voted on by stockholders. Holders of Class A common stock
and holders of Class B common stock will vote together as a single class on all matters submitted to a vote of the Company’s stockholders
except as required by law. Unless specified in the Company’s amended and restated certificate of incorporation, or as required by
applicable provisions of the Delaware General Corporate Law or applicable stock exchange rules, the affirmative vote of a majority of
the Company’s shares of common stock that are voted is required to approve any such matter voted on by its stockholders.
The Class
B common stock will automatically convert into Class A common stock upon the consummation of the initial Business Combination on a one-for-one
basis, subject to adjustment for stock splits, stock dividends, reorganizations, recapitalizations and the like, and subject to further
adjustment as provided herein. In the case that additional shares of Class A common stock or equity-linked securities are issued or deemed
issued in connection with the initial Business Combination, the number of Class A common stock issuable upon conversion of all Founder
Shares will equal, in the aggregate, on an as-converted basis, 20% of the total number of Class A common stock outstanding after
such conversion, including the total number of shares of Class A common stock issued, or deemed issued or issuable upon conversion or
exercise of any equity-linked securities or rights issued or deemed issued, by the Company in connection with or in relation to the consummation
of the initial Business Combination, excluding (i) any shares of Class A common stock redeemed by public stockholders in connection with
the initial Business Combination and (ii) any Class A common stock or equity-linked securities exercisable for or convertible into Class
A common stock issued, or to be issued, to any seller in the initial Business Combination and any warrants issued to the Sponsor, officers
or directors upon conversion of Working Capital Loans; provided that such conversion of Founder Shares will never occur on a less than
one-for-one basis.
Warrants –
The Company accounts for the 19,112,500 warrants, issued and outstanding at March 31, 2022 and December 31, 2021, in connection
with the IPO (10,062,500 Public Warrants and 9,050,000 Private Placement Warrants) in accordance with the guidance contained
in ASC 815-40. The Company concluded that the Public and Private Placement Warrants are considered indexed to the entity’s own stock
and meet other equity classification requirements. Therefore, Public and Private Placement Warrants are considered equity instruments
and are classified as such.
Each whole
warrant entitles the holder to purchase one share of Class A common stock at a price of $11.50 per share, subject to adjustment as discussed
herein. In addition, if (x) the Company issue additional shares of Class A common stock or equity-linked securities for capital raising
purposes in connection with the closing of the initial Business Combination at an issue price or effective issue price of less than $9.20
per share of Class A common stock (with such issue price or effective issue price to be determined in good faith by the Company’s
board of directors and, in the case of any such issuance to the initial stockholders or their affiliates, without taking into account
any Founder Shares held by the initial stockholders or such affiliates, as applicable, prior to such issuance), (the “Newly Issued
Price”), (y) the aggregate gross proceeds from such issuances represent more than 60% of the total equity proceeds, and interest
thereon, available for the funding of the initial Business Combination on the date of the consummation of the initial Business Combination
(net of redemptions), and (z) the volume weighted average trading price of the Company’s Class A common stock during the 20 trading
day period starting on the trading day after the day on which the Company consummates its initial Business Combination (such price, the
“Market Value”) is below $9.20 per share, the exercise price of the warrants will be adjusted (to the nearest cent) to be
equal to 115% of the higher of the Market Value and the Newly Issued Price, and the $18.00 per share redemption trigger price will be
adjusted (to the nearest cent) to be equal to 180% of the higher of the Market Value and the Newly Issued Price.
The
warrants will become exercisable on the later of 12 months from the closing of the IPO or 30 days after the completion of its initial
Business Combination, and will expire five years after the completion of the Company’s initial Business Combination, at 5:00 p.m.,
New York City time, or earlier upon redemption or liquidation.
The Company
has agreed that as soon as practicable, but in no event later than 15 business days after the closing of the initial Business Combination,
the Company will use its best efforts to file with the SEC and have an effective registration statement covering the shares of Class A
common stock issuable upon exercise of the warrants and to maintain a current prospectus relating to those shares of Class A common stock
until the warrants expire or are redeemed, as specified in the warrant agreement. If a registration statement covering the Class A common
stock issuable upon exercise of the warrants is not effective by the 60th business day after the closing of the initial Business Combination,
warrant holders may, until such time as there is an effective registration statement and during any period when the Company will have
failed to maintain an effective registration statement, exercise warrants on a “cashless basis” in accordance with Section
3(a)(9) of the Securities Act or another exemption. Notwithstanding the above, if the shares of Class A common stock are at the time of
any exercise of a warrant not listed on a national securities exchange such that they satisfy the definition of a “covered security”
under Section 18(b)(1) of the Securities Act, the Company may, at its option, require holders of public warrants who exercise their warrants
to do so on a “cashless basis” in accordance with Section 3(a)(9) of the Securities Act and, in the event the Company so elect,
it will not be required to file or maintain in effect a registration statement, and in the event the Company does not so elect, it will
use its best efforts to register or qualify the shares under applicable blue sky laws to the extent an exemption is not available.
Once the
warrants become exercisable, the Company may redeem the outstanding warrants (except as described herein with respect to the Private Placement
Warrants):
| ● | In
whole and not in part; |
| ● | at
a price of $0.01 per warrant; |
| ● | upon
a minimum of 30 days’ prior written notice of redemption given after the warrants become exercisable (the “30-day redemption
period”) to each warrant holder; and |
| ● | if,
and only if, the reported last sale price of the Class A common stock equals or exceeds $18.00 per share (as adjusted for stock splits,
stock dividends, reorganizations, recapitalizations and the like) for any 20 trading days within a 30-trading day period commencing once
the warrants become exercisable and ending three business days before the Company sends the notice of redemption to the warrant holders. |
The Private
Placement Warrants may not be transferred, assigned or sold, except to permitted transferees, until 30 days after the consummation of
an initial Business Combination, and will not be redeemable by the Company. The initial purchasers, or their permitted transferees, have
the option to exercise the Private Placement Warrants on a cashless basis. Otherwise, the Private Placement Warrants have terms and provisions
that are identical to those of the warrants sold as part of the units in the IPO.
Note
8 — Subsequent Events
The Company
evaluated subsequent events and transactions that occurred after the balance sheet date up to the date the unaudited condensed financial
statements were issued. The Company did not identify any subsequent events that would have required adjustment or disclosure in the financial
statements.